Form 4: Phathom Pharmaceuticals Director Michael F. Cola Reports Stock and Option Transactions

Director Michael F. Cola reported the acquisition of restricted stock units and stock options in Phathom Pharmaceuticals, as well as the disposal of common stock.

Summary

• Michael F. Cola, a director of Phathom Pharmaceuticals, reported changes in beneficial ownership on May 23, 2024.
• Cola acquired 10,500 shares of common stock through Restricted Stock Units (RSUs) granted under the Non-Employee Director Compensation Program.
• These RSUs will vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.
• Each RSU represents the right to receive one share of Phathom Pharmaceuticals common stock.
• Cola also acquired options to purchase 17,500 shares of common stock at an exercise price of $10.30, also under the Non-Employee Director Compensation Program.
• These options will vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.
• Additionally, Cola disposed of 29,298 shares of common stock.
• Following these transactions, Cola directly owns 29,298 shares of common stock and holds options for 17,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of director stock transactions. The acquisition of RSUs and options is generally positive, but the disposal of shares introduces a slightly negative element, though without further context, it's difficult to assess the impact.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of shareholders.
• The vesting schedule incentivizes continued service on the board.

Negatives

• The disposal of 29,298 shares of common stock by a director could be interpreted negatively by the market, although the reason for disposal is not specified.

Risks

• The value of the RSUs and stock options is contingent on the future performance of Phathom Pharmaceuticals' stock.
• The director's continued service on the board is necessary for the vesting of the RSUs and options.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of RSUs and stock options is tied to future service and the company's annual meetings.

Industry Context

This filing is a routine disclosure of insider transactions, common in the pharmaceutical industry where equity compensation is frequently used to incentivize executives and directors.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Pfizer also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and terms are generally comparable to industry standards, aligning with the goal of retaining and incentivizing board members.

Stakeholder Impact

• Shareholders may view the transactions as an alignment of interests between the director and the company's performance.
• Employees may see the equity grants as a positive sign of the company's commitment to its leadership.

Next Steps

• Monitor future filings for further transactions by the director.
• Track the vesting of the RSUs and stock options based on the director's continued service and the timing of the annual meetings.

Key Dates